Ayala
is a Delaware-based clinical-stage pharmaceutical company that researches and develops novel therapeutics for the treatment of cancer... Read moreAyala
is a Delaware-based clinical-stage pharmaceutical company that researches and develops novel therapeutics for the treatment of cancer... Read more
News
Apr 12, 2025
Pulse2.0
Ayala: OS Therapies: Acquisition Of Advaxis Immunotherapies Assets Completed
Jan 29, 2025
Citybizlist
Ayala: OS Therapies to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals
May 09, 2024
GlobeNewswire
Press Release: Ayala : Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations
Apr 16, 2024
Marketscreener
Ayala: Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Apr 03, 2024
Marketscreener
Ayala: Ayala Pharmaceuticals, Inc. Announces Departure of Roy Golan as Chief Financial Officer, Effective from June 25, 2024
Mar 26, 2024
Business Wire
Ayala: Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
Feb 20, 2024
centralcharts
Press Release: Ayala : Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
Feb 07, 2024
Pharamceutical Technology
Ayala: Immunome wins Ayala's Phase III desmoid tumour candidate for $50m
Nov 20, 2023
Marketscreener
Ayala: Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov 06, 2023
GlobalNewswire
Press Release: Ayala : Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
Ayala Competitors
1
2
3
4
5
6
7
8
9
10